Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis.

Rego de Figueiredo I, Simas FS, Ghiletchi A, Oliveira Torres J, Silva-Nunes J

Obesity (Silver Spring, Md.)4 Feb 2026Cited by 2 (Europe PMC)

PMID41640092PMCIDPMC13535706DOI10.1002/oby.70098PepBankPUB-41640092

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
One included study suggested that liraglutide could reduce fat mass in older adults with obesity.
In plain wordsOne included study suggested that liraglutide could reduce fat mass in older adults with obesity.
Peptide
Liraglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
3 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.
Summary · context
PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes.
Summary · context
Five studies involving 1229 participants were included.
Report a problemFND-4164009207
02HumanSystematic reviewSafety outcome
One included study suggested that liraglutide could reduce fat mass without worsening sarcopenia in older adults with obesity.
In plain wordsOne study suggested that liraglutide could reduce fat mass without worsening sarcopenia in older adults with obesity.
Peptide
Liraglutide
Outcome
Not applicableSarcopenia
Study
n: not reported in source
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
3 context sentences(design, population, supporting numbers)
Summary · context
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.
Summary · context
PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes.
Summary · context
Five studies involving 1229 participants were included.
Report a problemFND-4164009208

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 receptor agonist studies in adults with obesity, serious adverse events did not differ significantly between older and younger adults.
In plain wordsFor pooled GLP-1 receptor agonists in adults with obesity, serious adverse events did not differ significantly between older and younger adults.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Comparator
Younger adults
Outcome group
Adverse events · Whole body
Measurements
Pooled LOR
0.06
serious adverse events
Source sentences
Summary
No significant difference in serious adverse events was found between older and younger adults (pooled LOR: 0.06, p = 0.9).
5 context sentences(design, population, supporting numbers)
Summary · context
Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
Summary · context
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.
Summary · context
A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Summary · context
PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes.
Summary · context
Five studies involving 1229 participants were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4164009201
04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across studies of GLP-1 receptor agonists in adults with obesity, older adults had a nonsignificant trend toward lower nausea frequency than younger adults.
In plain wordsFor pooled GLP-1 receptor agonists in adults with obesity, older adults had a nonsignificant trend toward less nausea than younger adults.
Peptide
Liraglutide
Outcome
No significant changeNausea
Study
n: not reported in source
Comparator
Younger adults
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
LOR
−0.44
nausea
Source sentences
Summary
Older adults had a trend toward lower frequency of nausea (LOR: -0.44, p = 0.06) but higher incidence of constipation (LOR: 0.72, p = 0.02) and hypoglycemia (LOR: 0.97, p < 0.001).
5 context sentences(design, population, supporting numbers)
Summary · context
Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
Summary · context
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.
Summary · context
A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Summary · context
PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes.
Summary · context
Five studies involving 1229 participants were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4164009202
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across studies of GLP-1 receptor agonists in adults with obesity, older adults had higher constipation incidence than younger adults.
In plain wordsFor pooled GLP-1 receptor agonists in adults with obesity, older adults had more constipation than younger adults.
Peptide
Liraglutide
Outcome
IncreaseConstipation
Study
n: not reported in source
Comparator
Younger adults
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
LOR
0.72
constipation
Source sentences
Summary
Older adults had a trend toward lower frequency of nausea (LOR: -0.44, p = 0.06) but higher incidence of constipation (LOR: 0.72, p = 0.02) and hypoglycemia (LOR: 0.97, p < 0.001).
5 context sentences(design, population, supporting numbers)
Summary · context
Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
Summary · context
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.
Summary · context
A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Summary · context
PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes.
Summary · context
Five studies involving 1229 participants were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4164009203
06HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across studies of GLP-1 receptor agonists in adults with obesity, older adults had higher hypoglycemia incidence than younger adults.
In plain wordsFor pooled GLP-1 receptor agonists in adults with obesity, older adults had more hypoglycemia than younger adults.
Peptide
Liraglutide
Outcome
IncreaseHypoglycemia
Study
n: not reported in source
Comparator
Younger adults
Outcome group
Adverse events · Metabolic and weight
Measurements
LOR
0.97
hypoglycemia
Source sentences
Summary
Older adults had a trend toward lower frequency of nausea (LOR: -0.44, p = 0.06) but higher incidence of constipation (LOR: 0.72, p = 0.02) and hypoglycemia (LOR: 0.97, p < 0.001).
5 context sentences(design, population, supporting numbers)
Summary · context
Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
Summary · context
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.
Summary · context
A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Summary · context
PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes.
Summary · context
Five studies involving 1229 participants were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4164009204
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
Across studies of GLP-1 receptor agonists in adults with obesity, metabolic control was reported as comparable between older and younger adults.
In plain wordsFor pooled GLP-1 receptor agonists in adults with obesity, metabolic control was reported as comparable in older and younger adults.
Peptide
Liraglutide
Outcome
Not applicableMetabolic control
Study
n: not reported in source
Comparator
Younger adults
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Efficacy in metabolic and weight control was comparable.
5 context sentences(design, population, supporting numbers)
Summary · context
Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
Summary · context
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.
Summary · context
A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Summary · context
PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes.
Summary · context
Five studies involving 1229 participants were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4164009205
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
Across studies of GLP-1 receptor agonists in adults with obesity, weight control was reported as comparable between older and younger adults.
In plain wordsFor pooled GLP-1 receptor agonists in adults with obesity, weight control was reported as comparable in older and younger adults.
Peptide
Liraglutide
Outcome
Not applicableWeight control
Study
n: not reported in source
Comparator
Younger adults
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Efficacy in metabolic and weight control was comparable.
5 context sentences(design, population, supporting numbers)
Summary · context
Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
Summary · context
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.
Summary · context
A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Summary · context
PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes.
Summary · context
Five studies involving 1229 participants were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4164009206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.